Kcentra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to widespread warfarin use, high bleeding risk in anticoagulated patients, early adoption of pcc products, emergency department demand, hospital surgical safety needs.

The growth in the forecast period can be attributed to aging population on anticoagulants, rising emergency surgical procedures, improved awareness of pcc benefits, expansion of trauma care centers, growth in outpatient surgical volumes. Major trends in the forecast period include rising demand for rapid anticoagulation reversal, growth in emergency hemostasis management, expansion of surgical bleeding control therapies, increased use in trauma and critical care, strengthening hospital based coagulation protocols.

The rising prevalence of bleeding disorders is expected to drive the growth of the Kcentra market moving forward. Bleeding disorders, including hemophilia, von Willebrand disease (VWD), and acquired coagulopathies, are conditions that impair the blood's ability to clot, resulting in prolonged or excessive bleeding. The increasing prevalence of these disorders is attributed to genetic factors, enhanced diagnostic methods, and greater awareness, which have led to better identification of cases globally. Kcentra, a prothrombin complex concentrate, is used in the treatment of bleeding disorders, particularly in patients with vitamin K antagonists or warfarin-associated bleeding. For example, in December 2023, the World Federation of Hemophilia, a Canada-based international nonprofit organization, reported that the World Bleeding Disorders Registry recorded data from 13,343 individuals with hemophilia across 119 treatment centers in 44 countries in 2023, up from 12,296 individuals across 108 centers in 42 countries in 2022. As a result, the growing prevalence of bleeding disorders is contributing to the expansion of the Kcentra market.

Rising healthcare expenditure is also expected to fuel the Kcentra market moving forward. Healthcare expenditure refers to the total amount spent on health services, including investments in medical infrastructure, advanced therapies, emergency care, and surgical interventions. The increase in healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, higher service prices, increased demand for healthcare, technological advancements, rising drug costs, the impact of COVID-19, medical inflation, and income polarization. Healthcare expenditure for Kcentra is primarily allocated to treatments for the urgent reversal of anticoagulant-induced bleeding, with significant costs associated with its use in critical care and hospital settings. For instance, in May 2024, a report from the Office for National Statistics, a UK-based government agency, showed that total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. As a result, the rising healthcare expenditure is contributing to the growth of the Kcentra market.

A key trend in the Kcentra market is the approval of new therapies, such as Balfaxar (human prothrombin complex concentrate), which is driving competitive advancements in the industry. Balfaxar is designed for the urgent reversal of acquired coagulation factor deficiency induced by warfarin therapy in adult patients requiring urgent surgery or invasive procedures. For example, in July 2023, Octapharma USA, a U.S.-based pharmaceutical company, announced that Balfaxar (also known as Octaplex in Europe and Canada) had been granted approval by the U.S. Food and Drug Administration (FDA) for the emergency reversal of coagulation factor deficiencies caused by vitamin K antagonist (VKA) therapy, such as warfarin, in adult patients requiring urgent procedures. Balfaxar works by restoring blood coagulation by replenishing the deficient clotting factors caused by warfarin therapy. This approval represents a significant development in competitive therapies aimed at reversing anticoagulation effects, creating more options for managing bleeding complications.

Major companies operating in the kcentra market are CSL Behring.

North America was the largest region in the kcentra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kcentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kcentra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the kcentra market by increasing costs related to plasma fractionation, sterile formulation, and international pharmaceutical logistics. These effects are most pronounced in hospital and emergency department settings, particularly in regions dependent on imported coagulation products. Higher tariffs can strain hospital procurement budgets and affect rapid access during emergencies. At the same time, tariffs are encouraging domestic plasma processing, regional manufacturing investments, and stronger supply chain security for critical care medicines.

The kcentra market research report is one of a series of new reports that provides kcentra market statistics, including kcentra industry global market size, regional shares, competitors with a kcentra market share, detailed kcentra market segments, market trends and opportunities, and any further data you may need to thrive in the kcentra industry. This kcentra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kcentra is a medication designed for the urgent reversal of vitamin K antagonists, such as warfarin, in patients experiencing major bleeding or requiring urgent surgery. It is a prothrombin complex concentrate that provides rapid correction of clotting factors, aiding in the restoration of normal blood coagulation. Kcentra is typically administered intravenously in healthcare settings and is known for its effectiveness in quickly reversing anticoagulation effects, thereby reducing the risk of bleeding complications.

The primary indications for Kcentra include the urgent reversal of warfarin therapy, treatment of acquired coagulation factor deficiency, and management of major bleeding events. The urgent reversal of warfarin therapy involves rapidly restoring normal blood clotting function in patients at risk of bleeding, often using vitamin K, fresh frozen plasma, or coagulation factor concentrates. Kcentra is available in injectable formulations and lyophilized powders for reconstitution. It is used across a wide range of patient demographics, including pediatric, adult, and geriatric patients. The drug is distributed through various channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is utilized by different end users, such as hospitals, outpatient surgical centers, emergency departments, and specialty clinics.

The kcentra market consists of sales of profilnine, bebulin, and beriplex. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.